Sign up for the Abwiz Bio Newsletter to get actionable advice and exclusive deals direct to your inbox.
Phospho-p38 MAPK (Thr180/Tyr182) (E3) rabbit mAb
20 μL is enough antibody for at least 20 Western blots.
Customers Also Viewed
|Description||p38 mitogen-activated protein kinase (MAPK) participates in a signaling cascade that controls cellular responses to stress signals and cytokines (1). p38 MAPK isoforms p38α, p38β, p38γ (also known as Erk6 or SAPK3), and p38δ (also known as SAPK4) have been identified. p38 MAPK activation signal include inflammatory cytokines, UV light, osmotic shock, lipopolysaccharide (LPS), and growth factors (1). MKK3, MKK6, and SEK all activate p38 MAPK by phosphorylation at Thr180 and Tyr182. phospho-p38 MAPK has been shown to phosphorylate and activate MAPKAPK-2 (2) and to phosphorylate the transcription factors ATF-2 and MEF2 (3). A selective inhibitor of phospho-p38 MAPK is SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-imidazole), which inhibits the MAPKAPK-2 activation by p38 MAPK and subsequent phosphorylation of HSP27 (4). SB203580 inhibits p38 MAPK catalytic activity by binding the ATP-binding pocket, but does not inhibit p38 MAPK phosphorylation by upstream kinases (5).|
|Cross Reactivity||Predicted to work with mouse, rat and other homologues.|
|Formulation||1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Thr180/Tyr182 of human phospho p38 MAPK.|
|Validated Reactivity||Human, Mouse, Rat|
|Recommended Usage||1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.|
|References||1. Rouse, J. et al. (1994) Cell. 78:1027-1037.
2. Lee, J.C. et al. (1994) Nature. 372:739-746.
3. Raingeaud, J. et al. (1995) J. Biol. Chem. 270:7420-7426.
4. Cuenda, A. et al. (1995) FEBS Lett. 364:229-233.
5. Kumar, S. et al. (1999) Biochem. Biophys. Res. Commun. 263:825-831.
Flow cytometric analysis of C6 cells secondary antibody only negative control (blue) or untreated (red) or treated with staurosporine (green) using phospho-p38 MAPK (Thr180/Tyr182) antibody P38T180Y182-E3 0.01 µg/mL. Cat. #1156.
Peptide blocking flow cytometric analysis of C6 cells secondary antibody only negative control (light blue) or untreated (red) or treated with staurosporine (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-p38 MAPK (Thr180/Tyr182) antibody P38T180Y182-E3 at 5ng/mL. Cat. #1156.
Flow cytometric analysis of A431 cells secondary antibody only (blue) or untreated with 0.01 µg/mL of isotype control Cat. #2141 (orange) or untreated (red) or staurosporine-treated (green) using 0.01 µg/mL of Phospho-p38 MAPK (Thr180/Tyr182) antibody P38T180Y182-E3 Cat. #1156.
Flow cytometric analysis of C2C12 cells secondary antibody only negative control (blue) or 0.1 µg/mL of isotype control Cat. #2141 (orange) or untreated (red) or treated with staurosporine (green) using Phospho-p38 MAPK (Thr180/Tyr182) antibody P38T180Y182-E3 at 0.1 µg/mL. Cat. #1156.
Phospho-Histone H3 (Ser28) (D6) rabbit mAb PE conjugateCatalog#: 2047
Phospho-Chk2 (Thr68) (D12) rabbit mAb SureLight488 conjugateCatalog#: 2120
Phospho-Btk (Tyr223) (B4) rabbit mAb SureLight 488 conjugateCatalog#: 1175